Coya Therapeutics, Inc. (COYA)

Over the past six months, Coya Therapeutics' stock price has decreased. As of March 23, 2026, the share price was $4.22, a 36.54% decrease from $6.65 on March 24, 2025. Recent events include an $11.1 million private placement in January 2026, IND approvals for COYA 302 in ALS and FTD, and the initiation of the ALSTARS trial. In March 2026, the company reported a fourth-quarter revenue of $4.0 million and a basic EPS loss of $0.34, missing the consensus estimate. Wall Street Zen downgraded Coya Therapeutics from a "hold" to a "sell" rating, while other analysts reaffirmed "buy" ratings with price targets ranging from $14.00 to $18.00.

As a clinical-stage biotechnology company, Coya Therapeutics, Inc. does not have commercialized products subject to traditional demand seasonality. The demand for its product candidates is driven by clinical trials, regulatory approvals, and unmet medical needs.

Coya Therapeutics, Inc., headquartered in Houston, Texas, is a clinical-stage biotechnology company focusing on immunology to treat neurodegenerative, autoimmune, and metabolic diseases. The company develops therapies enhancing regulatory T cell function to address systemic and neuroinflammation. Its pipeline includes COYA 302, a biologic combination therapy in Phase 2 trials for ALS and being investigated for other neurodegenerative conditions; COYA 303, a combination of low-dose IL-2 and a GLP-1 receptor agonist in preclinical development for diseases driven by chronic inflammation; COYA 101, an autologous regulatory T-cell product candidate that has completed a Phase 2a clinical trial for ALS; COYA 301, a low-dose interleukin 2 Treg-enhancing biologic in IND-enabling studies for frontotemporal dementia; and COYA 201 and COYA 206, antigen-directed Treg-derived exosome product candidates in preclinical and discovery stages.

Coya Therapeutics, Inc. is headquartered in Houston, Texas, with clinical development activities extending to North America. The ALSTARS trial for COYA 302 is actively enrolling and dosing patients across approximately 25 clinical sites in the U.S. and Canada.

Coya Therapeutics' brand reputation has been influenced by clinical development and scientific publications. Positive contributions include publications linking inflammation to Parkinson's disease, preclinical data for COYA 303 demonstrating anti-inflammatory effects, publications demonstrating Treg dysfunction in Frontotemporal Dementia, results from a study demonstrating Treg enhancement and cognitive stability in Frontotemporal Dementia patients, FDA acceptance of the IND application for COYA 302 for FTD, Health Canada's acceptance of the CTA for the COYA 302 ALSTARS Trial for ALS, and the successful launch of the ALSTARS Phase 2 trial. A potential negative impact was the downgrade to a "sell" rating by Wall Street Zen in March 2026.

Coya Therapeutics, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 27.71% to 31.58% of the company's stock is owned by institutional investors, 4.42% by insiders, and around 64.00% by public companies and individual investors. As of December 2025, Coya Therapeutics had 57 active institutional owners. Major institutional shareholders include DME Capital Management, LP, and Vanguard Group Inc. Among individual investors, Howard Berman owns the most shares.